Biologics and Small Molecules in the Treatment of COVID-19

June 2020 | Volume 19 | Issue 6 | Features | 673 | Copyright © June 2020


Published online May 20, 2020

Dedee F. Murrell MD,a Lidia Rudnicka MD,b Swathi Shivakumar MBBS MD,c Martin Kassir MD,d Mohammad Jafferany MD,e Hassan Galadari MD,f Torello Lotti MD,g Roxanna Sadoughifar MD,h Zuzanna Sitkowska MS,i Mohamad Goldust MDj

aDepartment of Dermatology, St George Hospital, Faculty of Medicine, University of New South Wales, Sydney, Australia bDepartment of Dermatology, Medical University of Warsaw, Warsaw, Poland cCosmetiq Clinic, Pettah-Chacka Road, Trivandrum, Kerala, India dFounding director, Worldwide laser institute, Dallas, TX eCentral Michigan University, Saginaw, MI fCollege of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates gUniversity of Studies Guglielmo Marconi, Rome, Italy hUniversity of Rome G. Marconi, Rome, Italy; Bidarskincenter Tehran, Iran iDepartment of Dermatology, Medical University of Warsaw, Warsaw, Poland jUniversity of Rome G. Marconi, Rome, Italy; Department of Dermatology, University Hospital Basel, Basel, Switzerland

11. Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I. COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action. Dermatol Ther. 2020 Mar 11:e13298. doi: 10.1111/dth.13298.
12. Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020 Mar 18. pii:S0190-9622(20)30445-X. doi: 10.1016/j.jaad.2020.03.031
13. Deng X, Yu X, Pei J. Regulation of interferon production as a potential strategy for COVID-19 treatment. ArXiv200300751 Q-Bio [Internet]. 2020 Mar 2 (Accessed 2020 Mar 21); Available from: http://arxiv.org/abs/2003.00751
14. ALK is a therapeutic target for lethal sepsis | Science Translational Medicine [Internet]. (Accessed 2020 Mar 21). Available from: https://stm.sciencemag. org/content/9/412/eaan5689.abstract
15. Wang M, Sooreshjani MA, Mikek C, Opoku-Temeng C, Sintim HO. Suramin potently inhibits cGAMP synthase, cGAS, in THP1 cells to modulate IFN-β levels. Future Med Chem. 2018 01;10(11):1301–17.
16. COVID-19 Registered Trials and analysis. CEBM. (Accessed 2020 Mar 29). Available from: https://www.cebm.net/covid-19/registered-trials-and-analysis/
17. Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al. The potential role of IL-6 in monitoring severe case of coronavirus disease 2019 [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Mar [cited 2020 Mar 20]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.03.01.20029769
18. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 Apr 29.
19. EUSA Pharma initiates study of siltuximab to treat Covid-19 patients [Internet]. [cited 2020 Mar 21]. Available from: https://www.clinicaltrialsarena. com/news/eusa-pharma-siltuximab-study-covid-19/

AUTHOR CORRESPONDENCE

Mohamad Goldust MD mohamad.goldust@usb.ch